AssetMark’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
SL
AssetMark's KYMR Position: Q3 2026 in Review
AssetMark increased its Kymera Therapeutics (KYMR) stake by 48,438% in Q3 2026, buying an estimated $444K and bringing the position to 3,883 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.
AssetMark first reported a position in KYMR in Q2 2025 and has held it in 6 quarters since. 220 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- AssetMark held 3,883 shares of Kymera Therapeutics worth $434K as of Q3 2026.
- AssetMark bought 3,875 Kymera Therapeutics shares in Q3 2026, an estimated $444K.
- Kymera Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1280 holding.
- AssetMark first reported a position in Kymera Therapeutics in Q2 2025 and has held it in 6 quarters since.
- 220 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.